-
1
-
-
0029111738
-
Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - A clinical research center study
-
Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients - a clinical research center study. J Clin Endocrinol Metab 1995;80: 2768-2775.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 2768-2775
-
-
Newman, C.B.1
Melmed, S.2
Snyder, P.J.3
-
3
-
-
0029786520
-
Acromegaly
-
Melmed S. Acromegaly. Metabolism 1996;45:51-52.
-
(1996)
Metabolism
, vol.45
, pp. 51-52
-
-
Melmed, S.1
-
4
-
-
0029832211
-
Treatment options for acromegaly
-
Sheppard MC, Stewart PM. Treatment options for acromegaly. Metabolism 1996;45:63-64.
-
(1996)
Metabolism
, vol.45
, pp. 63-64
-
-
Sheppard, M.C.1
Stewart, P.M.2
-
5
-
-
0029810971
-
The role of somatostatin agonistic analogs in the treatment of acromegaly
-
Tolis G. The role of somatostatin agonistic analogs in the treatment of acromegaly. Metabolism 1996;45:109-110.
-
(1996)
Metabolism
, vol.45
, pp. 109-110
-
-
Tolis, G.1
-
6
-
-
0030668649
-
A risk-benefit assessment of octreotide in the treatment of acromegaly
-
van der Lely AJ, de HW, Lamberts SW A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Saf 1997;17:317-324.
-
(1997)
Drug Saf
, vol.17
, pp. 317-324
-
-
Van Der Lely, A.J.1
De, H.W.2
Lamberts, S.W.3
-
7
-
-
0025783499
-
Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group
-
Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991;151:1573-1578.
-
(1991)
Arch Intern Med
, vol.151
, pp. 1573-1578
-
-
Vance, M.L.1
Harris, A.G.2
-
8
-
-
0031022831
-
Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
-
Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 18-22
-
-
Caron, P.1
Morange-Ramos, I.2
Cogne, M.3
Jaquet, P.4
-
9
-
-
0028828426
-
Sandostatin LAR in acromegalic patients: A dose-range study
-
Flogstad AK, Halse J, Haldorsen T, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995;80:3601-3607.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 3601-3607
-
-
Flogstad, A.K.1
Halse, J.2
Haldorsen, T.3
-
10
-
-
0028286788
-
Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide
-
Marek J, Hana V, Krsek M, et al. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-26.
-
(1994)
Eur J Endocrinol
, vol.131
, pp. 20-26
-
-
Marek, J.1
Hana, V.2
Krsek, M.3
-
11
-
-
0028222326
-
Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide
-
Morange I, De Boisvillers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79:145-151.
-
(1994)
J Clin Endocrinol Metab
, vol.79
, pp. 145-151
-
-
Morange, I.1
De Boisvillers, F.2
Chanson, P.3
-
12
-
-
0031036540
-
Depot somatostatin analogs - A new first line therapy for acromegaly
-
Robbins RJ. Depot somatostatin analogs - a new first line therapy for acromegaly. J Clin Endocrinol Metab 1997; 82:15-17.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 15-17
-
-
Robbins, R.J.1
-
13
-
-
0028864383
-
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
-
Stewart PM, Kane KF, Stewart SE, et al. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995;80: 3267-3272.
-
(1995)
J Clin Endocrinol Metab
, vol.80
, pp. 3267-3272
-
-
Stewart, P.M.1
Kane, K.F.2
Stewart, S.E.3
-
14
-
-
0031930952
-
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
-
Davies PH, Stewart SE, Lancranjan L, et al. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 1998; 48:311-316.
-
(1998)
Clin Endocrinol (Oxf)
, vol.48
, pp. 311-316
-
-
Davies, P.H.1
Stewart, S.E.2
Lancranjan, L.3
-
15
-
-
0031023098
-
Sandostatin LAR in acromegalic patients: Long-term treatment
-
Flogstad AK, Halse J, Bakke S, et al. Sandostatin LAR in acromegalic patients: Long-term treatment. J Clin Endocrinol Metab 1997;82:23-28.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 23-28
-
-
Flogstad, A.K.1
Halse, J.2
Bakke, S.3
-
16
-
-
0030853659
-
Acromegaly and its treatment
-
discussion S67-71:S49-S51
-
Lamberts SW. Acromegaly and its treatment. J Endocrinol 1997;155(Suppl 1):S49-51; discussion S67-71:S49-S51.
-
(1997)
J Endocrinol
, vol.155
, Issue.1 SUPPL.
-
-
Lamberts, S.W.1
-
17
-
-
0025190143
-
Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety
-
Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety. Ann Intern Med 1990;112:173-181.
-
(1990)
Ann Intern Med
, vol.112
, pp. 173-181
-
-
Ho, K.Y.1
Weissberger, A.J.2
Marbach, P.3
Lazarus, L.4
-
18
-
-
0031028364
-
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
-
Shimon I, Taylor JE, Dong JZ, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99:789-798.
-
(1997)
J Clin Invest
, vol.99
, pp. 789-798
-
-
Shimon, I.1
Taylor, J.E.2
Dong, J.Z.3
-
19
-
-
0030850528
-
Structure and function of somatostatin receptors in growth hormone control
-
discussion S7-8:S3-S6
-
Shimon I, Melmed S. Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 1997;155(Suppl 1):S3-6; discussion S7-8:S3-S6.
-
(1997)
J Endocrinol
, vol.155
, Issue.1 SUPPL.
-
-
Shimon, I.1
Melmed, S.2
-
20
-
-
0030690974
-
Somatostatin receptor (SSTR) subtype- selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
-
Shimon I, Yan X, Taylor JE, et al. Somatostatin receptor (SSTR) subtype- selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100:2386-2392.
-
(1997)
J Clin Invest
, vol.100
, pp. 2386-2392
-
-
Shimon, I.1
Yan, X.2
Taylor, J.E.3
-
21
-
-
2342516114
-
Effect of two somatostatin analogs with different selectivity for sub-type 2 and 5 of the somatostatin receptor on growth hormone (GH) secretion in human GH-secreting adenomas cultured in vitro
-
June 24-27, New Orleans, Louisiana, USA [P2-212]
-
Giustina A, Bonfanti C, Bollati A, et al. Effect of two somatostatin analogs with different selectivity for sub-type 2 and 5 of the somatostatin receptor on growth hormone (GH) secretion in human GH-secreting adenomas cultured in vitro. The 80th Annual Meeting of the Endocrine Society, 1998 June 24-27, New Orleans, Louisiana, USA [P2-212].
-
(1998)
The 80th Annual Meeting of the Endocrine Society
-
-
Giustina, A.1
Bonfanti, C.2
Bollati, A.3
-
22
-
-
0030993137
-
Combined cabegoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency
-
Cesario F, Borretta G, Meineri I, et al. Combined cabegoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency. J Pediatr Endocrinol Metab 1997;10:231-236.
-
(1997)
J Pediatr Endocrinol Metab
, vol.10
, pp. 231-236
-
-
Cesario, F.1
Borretta, G.2
Meineri, I.3
-
23
-
-
0030790217
-
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy
-
Colao A, Lombardi G. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. J Clin Endocrinol Metab 1997;82:2756.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 2756
-
-
Colao, A.1
Lombardi, G.2
-
24
-
-
0030807953
-
Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy
-
Delgrange E, Donckier J. Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. J CLIn Endocrinol Metab 1997;82:2755-2756.
-
(1997)
J CLIn Endocrinol Metab
, vol.82
, pp. 2755-2756
-
-
Delgrange, E.1
Donckier, J.2
-
25
-
-
8244250765
-
Treatment of macroprolactinoma with cabergoline: A study of 85 patients
-
Ferrari Cl, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409-413.
-
(1997)
Clin Endocrinol (Oxf)
, vol.46
, pp. 409-413
-
-
Ferrari, Cl.1
Abs, R.2
Bevan, J.S.3
-
26
-
-
0026497610
-
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group
-
Webster J, Piscitelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) 1992;37:534-541.
-
(1992)
Clin Endocrinol (Oxf)
, vol.37
, pp. 534-541
-
-
Webster, J.1
Piscitelli, G.2
Polli, A.3
-
27
-
-
0027247927
-
The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group
-
Webster J, Piscitelli G, Polli A, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: An open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol (Oxf) 1993;39:323-329.
-
(1993)
Clin Endocrinol (Oxf)
, vol.39
, pp. 323-329
-
-
Webster, J.1
Piscitelli, G.2
Polli, A.3
-
28
-
-
0026516108
-
Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
-
Brue T, Pellegrini I, Gunz G, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endorinol Metab 1992;74: 577-584.
-
(1992)
J Clin Endorinol Metab
, vol.74
, pp. 577-584
-
-
Brue, T.1
Pellegrini, I.2
Gunz, G.3
-
30
-
-
0027215263
-
Long-term treatment of macroprolactinomas with CV 205-502
-
Kvistborg A, Halse J, Bakke S, et al. Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh) 1993;128:301-307.
-
(1993)
Acta Endocrinol (Copenh)
, vol.128
, pp. 301-307
-
-
Kvistborg, A.1
Halse, J.2
Bakke, S.3
-
31
-
-
0023154459
-
CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion
-
Rasmussen C, Bergh T, Wide L, Brownell J. CV 205-502: A new long-acting drug for inhibition of prolactin hypersecretion. Clin Endocrinol (Oxf) 1987;26:321-326.
-
(1987)
Clin Endocrinol (Oxf)
, vol.26
, pp. 321-326
-
-
Rasmussen, C.1
Bergh, T.2
Wide, L.3
Brownell, J.4
-
32
-
-
0025728631
-
The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine
-
van der Lely AJ, Brownell J, Lamberts SW. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72:1136-1141.
-
(1991)
J Clin Endocrinol Metab
, vol.72
, pp. 1136-1141
-
-
Van Der Lely, A.J.1
Brownell, J.2
Lamberts, S.W.3
-
34
-
-
0031792509
-
Cabergoline in the treatment of acromegaly: A study in 64 patients
-
Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 374-378
-
-
Abs, R.1
Verhelst, J.2
Maiter, D.3
-
35
-
-
0031026529
-
Effect of different dopaminergic agents in the treatment of acromegaly
-
Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 518-523
-
-
Colao, A.1
Ferone, D.2
Marzullo, P.3
-
36
-
-
0030774607
-
Evidence for dopamine agonists in the treatment of acromegaly
-
Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 1997;155(Suppl 1):S59-60: S59-S60.
-
(1997)
J Endocrinol
, vol.155
, Issue.1 SUPPL.
-
-
Jaquet, P.1
-
38
-
-
0003289231
-
A six-week, double blind, placebo controlled study of a growth hormone antagonist, B 2036-PEG (Trovert™), in acromegalic patients
-
June 24-27, New Orleans, Louisiana, USA [OR4-1]
-
van der Lely AJ, Lamberts SW, Barkan A, et al. A six-week, double blind, placebo controlled study of a growth hormone antagonist, B 2036-PEG (Trovert™), in acromegalic patients. The 80th Annual Meeting of the Endocrine Society, 1998 June 24-27, New Orleans, Louisiana, USA [OR4-1].
-
(1998)
The 80th Annual Meeting of the Endocrine Society
-
-
Van Der Lely, A.J.1
Lamberts, S.W.2
Barkan, A.3
|